Literature DB >> 17984346

No depletion of Wolbachia from Onchocerca volvulus after a short course of rifampin and/or azithromycin.

Frank O Richards1, Josef Amann, Byron Arana, George Punkosdy, Robert Klein, Carlos Blanco, Beatriz Lopez, Carlos Mendoza, Alfredo Domínguez, Jeannette Guarner, James H Maguire, Mark Eberhard.   

Abstract

Endosymbionic Wolbachia bacteria inside adult Onchocerca volvulus worms (causing river blindness) are necessary for female worm fertility. We evaluated whether rifampin and/or azithromycin used in a five-day course could kill Wolbachia. In an open-label trial in Guatemala, 73 patients with 134 palpable onchocercal nodules were randomized into four treatment groups: rifampin, azithromycin, a combination of the two drugs, and controls (multivitamins). After five days of antibiotic treatment, all participants received a single dose of ivermectin on day 6. Nine months after treatment, the nodules were removed and the worms were examined. Skin snips to determine microfilariae were obtained at baseline and nine months. There were no significant differences between any of the treatment groups in the condition of the worms in the nodules, the presence of Wolbachia surface protein, or the number of microfilariae in skin. Short courses with these antibiotics will not clear Wolbachia from O. volvulus.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17984346

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN: 0002-9637            Impact factor:   2.345


  10 in total

1.  Efficacy of 2- and 4-week rifampicin treatment on the Wolbachia of Onchocerca volvulus.

Authors:  Sabine Specht; Sabine Mand; Yeboah Marfo-Debrekyei; Alexander Yaw Debrah; Peter Konadu; Ohene Adjei; Dietrich W Büttner; Achim Hoerauf
Journal:  Parasitol Res       Date:  2008-08-05       Impact factor: 2.289

2.  Effects of 6-week azithromycin treatment on the Wolbachia endobacteria of Onchocerca volvulus.

Authors:  Achim Hoerauf; Yeboah Marfo-Debrekyei; Marcelle Büttner; Alexander Yaw Debrah; Peter Konadu; Sabine Mand; Ohene Adjei; Dietrich W Büttner
Journal:  Parasitol Res       Date:  2008-04-18       Impact factor: 2.289

3.  Efficacy of three-week oxytetracycline or rifampin monotherapy compared with a combination regimen against the filarial nematode Onchocerca ochengi.

Authors:  Germanus S Bah; Emma L Ward; Abhishek Srivastava; Alexander J Trees; Vincent N Tanya; Benjamin L Makepeace
Journal:  Antimicrob Agents Chemother       Date:  2013-11-18       Impact factor: 5.191

4.  River blindness: an old disease on the brink of elimination and control.

Authors:  Kevin L Winthrop; Joao M Furtado; Juan C Silva; Serge Resnikoff; Van C Lansingh
Journal:  J Glob Infect Dis       Date:  2011-04

Review 5.  Repurposing drugs for the treatment and control of helminth infections.

Authors:  Gordana Panic; Urs Duthaler; Benjamin Speich; Jennifer Keiser
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2014-07-30       Impact factor: 4.077

Review 6.  Onchocerciasis drug development: from preclinical models to humans.

Authors:  Adela Ngwewondo; Ivan Scandale; Sabine Specht
Journal:  Parasitol Res       Date:  2021-10-13       Impact factor: 2.289

7.  Immunisation with a multivalent, subunit vaccine reduces patent infection in a natural bovine model of onchocerciasis during intense field exposure.

Authors:  Benjamin L Makepeace; Siv Aina Jensen; Sandra J Laney; Charles K Nfon; Leo M Njongmeta; Vincent N Tanya; Steven A Williams; Albert E Bianco; Alexander J Trees
Journal:  PLoS Negl Trop Dis       Date:  2009-11-10

Review 8.  Research for new drugs for elimination of onchocerciasis in Africa.

Authors:  Annette C Kuesel
Journal:  Int J Parasitol Drugs Drug Resist       Date:  2016-05-19       Impact factor: 4.077

9.  Short-Course, High-Dose Rifampicin Achieves Wolbachia Depletion Predictive of Curative Outcomes in Preclinical Models of Lymphatic Filariasis and Onchocerciasis.

Authors:  Ghaith Aljayyoussi; Hayley E Tyrer; Louise Ford; Hanna Sjoberg; Nicolas Pionnier; David Waterhouse; Jill Davies; Joanne Gamble; Haelly Metuge; Darren A N Cook; Andrew Steven; Raman Sharma; Ana F Guimaraes; Rachel H Clare; Andrew Cassidy; Kelly L Johnston; Laura Myhill; Laura Hayward; Samuel Wanji; Joseph D Turner; Mark J Taylor; Stephen A Ward
Journal:  Sci Rep       Date:  2017-03-16       Impact factor: 4.379

Review 10.  Anti-Wolbachia therapy for onchocerciasis & lymphatic filariasis: Current perspectives.

Authors:  Wan Aliaa Wan Sulaiman; Joseph Kamtchum-Tatuene; Mohd Hazmi Mohamed; Vasudevan Ramachandran; Siew Mooi Ching; Sazlyna Mohd Sazlly Lim; Hasnur Zaman Hashim; Liyana Najwa Inche Mat; Fan Kee Hoo; Hamidon Basri
Journal:  Indian J Med Res       Date:  2019-06       Impact factor: 2.375

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.